Literature DB >> 24926027

Modeling scenarios for the end of AIDS.

Viviane D Lima1, Harsha Thirumurthy2, James G Kahn3, Jorge Saavedra4, Carlos F Cárceres5, Alan Whiteside6.   

Abstract

At the end of 2012, 3 decades after the human immunodeficiency virus (HIV) was first identified, neither a cure nor a fully preventive vaccine was available. Despite multiple efforts, the epidemic remains an exceptional public health challenge. At the end of 2012, it was estimated that, globally, 35 million people were living with HIV, 2.3 million had become newly infected, and 1.6 million had died from AIDS-related causes. Despite substantial prevention efforts and increases in the number of individuals on highly active antiretroviral therapy (HAART), the epidemic burden continues to be high. Here, we provide a brief overview of the epidemiology of HIV transmission, the work that has been done to date regarding HIV modeling in different settings around the world, and how to finance the response to the HIV epidemic. In addition, we suggest discussion topics on how to move forward with the prevention agenda and highlight the role of treatment as prevention (TasP) in curbing the epidemic.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV epidemic; TasP; mathematical models; prevention; treatment as prevention

Mesh:

Year:  2014        PMID: 24926027      PMCID: PMC4141492          DOI: 10.1093/cid/ciu339

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  23 in total

Review 1.  The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models.

Authors:  Sally Blower; Erin Bodine; James Kahn; Willi McFarland
Journal:  AIDS       Date:  2005-01-03       Impact factor: 4.177

Review 2.  The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.

Authors:  Julio S G Montaner; Robert Hogg; Evan Wood; Thomas Kerr; Mark Tyndall; Adrian R Levy; P Richard Harrigan
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

3.  Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.

Authors:  Reuben M Granich; Charles F Gilks; Christopher Dye; Kevin M De Cock; Brian G Williams
Journal:  Lancet       Date:  2008-11-27       Impact factor: 79.321

4.  A tale of two futures: HIV and antiretroviral therapy in San Francisco.

Authors:  S M Blower; H B Gershengorn; R M Grant
Journal:  Science       Date:  2000-01-28       Impact factor: 47.728

5.  Epidemiological parameters of HIV transmission.

Authors:  R M Anderson; R M May
Journal:  Nature       Date:  1988-06-09       Impact factor: 49.962

6.  Improved employment and education outcomes in households of HIV-infected adults with high CD4 cell counts: evidence from a community health campaign in Uganda.

Authors:  Harsha Thirumurthy; Gabriel Chamie; Vivek Jain; Jane Kabami; Dalsone Kwarisiima; Tamara D Clark; Elvin Geng; Maya L Petersen; Edwin D Charlebois; Moses R Kamya; Diane V Havlir
Journal:  AIDS       Date:  2013-02-20       Impact factor: 4.177

7.  Can highly active antiretroviral therapy reduce the spread of HIV?: A study in a township of South Africa.

Authors:  Bertran Auvert; Sylvia Males; Adrian Puren; Dirk Taljaard; Michel Caraël; Brian Williams
Journal:  J Acquir Immune Defic Syndr       Date:  2004-05-01       Impact factor: 3.731

8.  Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.

Authors:  Viviane D Lima; Karissa Johnston; Robert S Hogg; Adrian R Levy; P Richard Harrigan; Aranka Anema; Julio S G Montaner
Journal:  J Infect Dis       Date:  2008-07-01       Impact factor: 5.226

9.  The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men.

Authors:  Alethea W McCormick; Rochelle P Walensky; Marc Lipsitch; Elena Losina; Heather Hsu; Milton C Weinstein; A David Paltiel; Kenneth A Freedberg; George R Seage
Journal:  Clin Infect Dis       Date:  2007-03-09       Impact factor: 9.079

10.  A test of financial incentives to improve warfarin adherence.

Authors:  Kevin G Volpp; George Loewenstein; Andrea B Troxel; Jalpa Doshi; Maureen Price; Mitchell Laskin; Stephen E Kimmel
Journal:  BMC Health Serv Res       Date:  2008-12-23       Impact factor: 2.655

View more
  2 in total

Review 1.  Modeling the implementation of universal coverage for HIV treatment as prevention and its impact on the HIV epidemic.

Authors:  Roger Ying; Ruanne V Barnabas; Brian G Williams
Journal:  Curr HIV/AIDS Rep       Date:  2014-12       Impact factor: 5.071

2.  Comparative assessment of five trials of universal HIV testing and treatment in sub-Saharan Africa.

Authors:  Delphine Perriat; Laura Balzer; Richard Hayes; Shahin Lockman; Fiona Walsh; Helen Ayles; Sian Floyd; Diane Havlir; Moses Kamya; Refeletswe Lebelonyane; Lisa A Mills; Velephi Okello; Maya Petersen; Deenan Pillay; Kalpana Sabapathy; Kathleen Wirth; Joanna Orne-Gliemann; François Dabis
Journal:  J Int AIDS Soc       Date:  2018-01       Impact factor: 5.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.